Brenus Pharma raised $25M in a Series A funding round led by Angelor to accelerate clinical trials for its precision cancer vaccines.
Brenus Pharma raised $25M in a Series A funding round led by Angelor to accelerate clinical trials for its precision cancer vaccines.
09/18/24, 5:37 AM
Location
lyonMoney raised
$25 million
Industry
therapeutics
biotechnology
health care
Round Type
series a
Investors
Stéphane Legastelois, Jacques Gardette, Investsud, Noshaq, Crédit Agricole Centre Est, Crédit Agricole Centre France, Ui Investissement, Angelor
Brenus Pharma, a biotech company developing cancer vaccines, has completed a $25 million Series A financing round. This funding will fully support the first-in-human proof-of-concept for its STC-1010 cancer vaccine.
Company Info
Location
lyon, auvergne rhône alpes, france
Additional Info
Brenus Pharma is a biotech company that specializes in the development of precision cancer vaccines. Their innovative technology platform, STC, utilizes an in-depth understanding of cancer complexity to create new treatment solutions. With a focus on transforming patient care, they aim to enhance immunotherapy outcomes for cancer patients. The company is dedicated to advancing its pipeline, featuring multiple candidates aimed at various solid tumor types.